biostudies-literatureHahn NMNCINCI NIH HHS3003-3011https://www.ebi.ac.uk/biostudies/studies/S-EPMC5462889biostudies-literatureUnknown23(12)<b>Purpose:</b> To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population.<b>Experimental Design:</b> A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (<u>></u>2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or <i>FGFR3</i> mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate.<b>Results:</b> Between 11/2013 and 10/2014, 13 patientClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.PMC5462889P30 CA006973P30CA006973P30 CA082709Masterson TAGardner TAGreenberg REHahn NMLiu ZBaras AJones DRRoss AELoman RLCheng LGeynisman DMChapman CSandusky GETsongalis GJAlbany CGallagher TBihrle RBreen TFoster RSNetto GJMoore MLBivalacqua TJMcElyea KKoch MOTurner SADe Abreu FBPlimack ERPark JCReed AfalseA Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.<b>Purpose:</b> To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population.<b>Experimental Design:</b> A multi-site pilot phase II trial was conducted. Key eligibility criteria included the following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (<u>></u>2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or <i>FGFR3</i> mutations (Mut+) assessed in a CLIA-licensed laboratory. Patients received oral dovitinib 500 mg daily (5 days on/2 days off). The primary endpoint was 6-month TURBT-confirmed complete response (CR) rate.<b>Results:</b> Between 11/2013 and 10/2014, 13 patient2017-01-01T00:00:00Z2017 Jun2026-05-04T21:00:44.901Z2019-03-26T23:41:24ZS-EPMC54628892793241610.1158/1078-0432.CCR-16-226710.1158/1078-0432.ccr-16-2267